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glands and tumor cells. Negligible androgen levels prevent stimulation of the intracellular receptor in the tumor cell, reducing
PSA synthesis and growth factors.
Objectives. To demonstrate the therapeutic beneﬁts and tolerance to abiraterone in elderly patients with metastatic castration-
resistant prostate cancer.
Methods. 82 year oldman, diagnosedwithprostate adenocarcinoma in 2005 (75 year old), PSA23, Gleason 6, T2b. Received complete
androgen deprivation therapy alone (anti-androgen and GnRH agonist), follow-up examination showed PSA 0,04 decline in 2006,
then progression to PSA 19,4 and bone scan suggestive of pelvic bone metastasis (2011). Discontinued treatment with anti-
androgen. PSA rise to 43.74 in January 2012, 10mg/24h prednisone prescribed. Follow-up showed PSA rise to 61 and alkaline
phosphatase 300 in August 2012. Bone scan suggested metastasis in iliac and sacrum bone. Patient refers mild pain in rest
and moderate pain while moving, no other symptoms associated. Karnosfky 95%, the CT extension study showed large bone
metastatic spread andno visceral or lymphnode involvement. Follow-up showed PSA 140, alkaline phosphatase 501, testosterone
level less than3ng/dl inOctober 2012. Abiraterone acetate 1000mgdaily andprednisone 5mgBIDprescribed. Zoledronic acid 4mg
iv/28 days and calcium and vitamin D oral. Pain management with oxycodone–naloxone 20/10/12h and ibuprofen 600mg/12h.
Results. Follow-up showed decline of PSA 27, alkaline phosphatase 300 and pain control improvement with no effect on blood
test results including liver function (normal hepatic enzymes level) in February 2013 (4 months after treatment start).
Conclusions. Abiraterone demonstrates its feasibility as therapeutic choice for elderly patients due to good tolerance.
http://dx.doi.org/10.1016/j.rpor.2013.03.469
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Introduction. Clinical evidences support dose escalation radiotherapy for unfavorable prostate cancer (PCa). To achieve it, we
combine Ir-192 High Dose Rate Brachytherapy (HDR-BT) with External Beam Radiotherapy (EBRT).
Purpose. Evaluation of acute urinary and intestinal toxicity during the following 6 months after treatment. Since almost all
patients were under androgen deprivation therapy (ATD), sexual toxicity has not been analyzed.
Methods. Between August 2010 and May 2012, 67 patients with intermediate/high risk PCa were treated. Median age: 75 (62–82).
Median follow-up: 14 months (6–29). Five patients had previous TURP and 3 had previous adenomectomy. EBRT administration
was 200 cGy/fraction, 5/week. Median needles used for HDR-BT procedure was 18 (12–27). If seminal vesicles involvement (21
patients), a single fraction of 9–9.5Gy HDR-BT plus 60Gy EBRT to pelvis and/or prostate-vesicles, was administrated. When
seminal vesicles were not inﬁltrated (46 patients), a single fraction of 15Gy HDR-BT plus 46Gy EBRT to pelvis or prostate-
vesicles. Sixty-one patients included ATD for 6 months in intermediate (24 patients) and 12–36 months in high risk PCa (37
patients). Toxicity evaluated following RTOG/EORTC criteria.
Results. After one month: 18 patients (26.8%) presented urinary toxicity; 16 G1 cases (dysuria and/or urgency), 1 G2 case (nocturia)
and 1 G4 case (complete urinary retention). Three patients presented intestinal G1 toxicity (diarrhea and/or mild bleeding). After
three months: 17 patients (25.3%) presented urinary toxicity; 13 G1 cases, 3 G2 cases and only one G4. Four G1 intestinal toxicity
cases were observed. After six months: 17 patients (25.3%) presented urinary toxicity; 10 G1 cases, 6 G2 cases, and 1 G4 case. Only
one patient presented G1 intestinal toxicity.
Conclusion. We found acceptable acute toxicity results. Main symptoms were dysuria and nocturia, most of them Grade 1. Only
three urinary G4 cases observed along the analyzed period. Intestinal toxicity cases were few and mild.
http://dx.doi.org/10.1016/j.rpor.2013.03.470
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Introduction. Recent publications have indicated that the ˛/ˇ ratio for prostate carcinoma is much lower than previously estab-
lished, suggesting that these tumours are much more sensitive to the dose administered per fraction. We do not know if the
hypofractionated treatment provides clinical beneﬁt in the treatment of prostate tumours.
Purpose. Assessment of the acute toxicity in patients diagnosed with prostate carcinoma and treated with hypofractionated
radiotherapy.
Methods and material. Between January 2012 and May 2012, 78 men were treated at the Hospitalary Radiophysics Unit of the
Hospital Complex of Jaén with ages comprised between 46 and 78 years old (average 68.3 years old), KPS 90-100%. They were
diagnosed with prostate adenocarcinoma, PSA between 4 and 188ngr/ml (average 16.39), Gleason 6 (56.5%) – 7 (23%) – 8 (9%) – 9
(5%) –others (6.5%), clinical stage T1c (65.4%), T2 (19.2%), T3 (15.4%). 78% of the cases were treated with androgen deprivation.
S312 reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S309–S336
Results. The dose administered was from 69.9 to 75.9Gy (average 74.2Gy), 5 days a week, in a fractionation of 2.3Gy per day (97%),
with 7 ﬁelds (97%) shaped three-dimensionally and photons of 18MV. The tolerance was excellent, showing no gastrointestinal
toxicity in 88.5%, G1 in 11.5%. Genitourinary toxicity was G0 in 55%, G1 in 40%, G2 in 5%.
Conclusion. The hypofractionated treatment is safe, showing minimal acute toxicity. Subsequently we will assess the long-term
toxicity, monitoring clinical and analytically through PSA control.
http://dx.doi.org/10.1016/j.rpor.2013.03.471
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Introduction. Despite recommendations in international guidelines, speciﬁc treatment depends on additional prognostic, clinical,
and personal factors. Relevant issues in the personalized treatment of high-risk prostate cancer (HRPC) include dose escalation,
treatment volumes, androgen deprivation therapy (ADT) strategy, and expected beneﬁts.
Objectives. To assess the recommendations of radiation oncologists in controversial areas of HRPC treatment.
Methods. The ÁGORA project involved 18 radiation oncologists and comprised 4 phases: (1) identiﬁcation of controversial areas
in the treatment of HRPC with aLHRH; (2) selection of speciﬁc literature; (3) preparation of case reports and questionnaires in 4
settings; (4) discussion of the case reports at regional meetings (May–July 2011). Therapeutic procedures were classiﬁed as “highly
recommendable”, “recommendable in some cases”, or “not recommendable/not applicable”. The dispersion of the responses was
considered to indicate consensus (SD<0.15) or high variability (SD>0.85).
Results. In young sexually active patients with HRPC (1 risk factor) and low IPSS, the most widely accepted treatment was neoadju-
vantHT (2–3months+ concomitant RT+adjuvantHT 24months) (SEM0.14). In young sexually active patientswithmoderate IPSS,
the consensus reached (SEM 0) was neoadjuvant HT 2–3 months+RT+adjuvant HT 24 months. In older, sexually inactive patients
with high IPSS, consensus was reached (SEM 0) on offering neoadjuvant HT 2–3 months+ concomitant treatment+adjuvant HT
24 months. In elderly patients with HRPC (1 risk factor) and a moderate post-TUR IPSS, the most accepted treatment (SEM 0.25)
was neoadjuvant HT 3 months+ concomitant ADT/RT.
Conclusions. Given the life expectancy of patients with HRPC, radiation oncologists agree that the ﬁrst option to be offered is
the combination of long-term HT combined with external RT. Treatment decisions in this group depend mainly on age and
unfavorable prognostic factors.
http://dx.doi.org/10.1016/j.rpor.2013.03.472
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Introduction. Both the CAPORT and AEU studies report a high prevalence of intermediate-risk prostate cancer (IRPC). Despite
recommendations in international guidelines, speciﬁc treatment depends on various prognostic, clinical, and personal factors.
Objectives. To assess radiation oncologists recommendations in controversial scenarios in IRPC and its treatment.
Methods. The ÁGORA project involved 18 radiation oncologists and comprised 4 phases: (1) identiﬁcation of controversial areas
in the treatment of IRPC with antigen deprivation (AD); (2) selection of speciﬁc literature; (3) preparation of case reports and
questionnaires in 4 settings; (4) discussion of the case reports at regional meetings (May–July 2011). Therapeutic procedures were
classiﬁed as “highly recommendable”, “recommendable in some cases”, or “not recommendable/not applicable”. The dispersion
of the responses was considered to indicate consensus (SD<0.15) or high variability (SD>0.85).
Results. In young sexually active patients with IRPC (1 factor) and low IPSS, the strongest agreement was for treatment consid-
ered inappropriate: Active monitoring and the combination of radiotherapy and bicalutamide 150mg/d. A broad consensus was
reached for radiotherapy combined with short-term AD and for brachytherapy. Consensus was weaker with respect to radical
prostatectomy and radiotherapy alone. In young sexually active patients with IRPC (>1 factor) and moderate IPSS, external radio-
therapy and short-term AD (4–6 months) was highly recommended. In older sexually inactive IRPC with a high IPSS, consensus
was reached on neoadjuvant AD 3 months+ concomitant radiotherapy. Brachytherapy alone should not be offered. No consensus
